Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NurExone BiologicFRA:J90 +2.50%38 EV-to-EBITDA is -5.30 as of Aug. 26, 2026. GuruFocus rates FRA:J90 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 413 Biotechnology companies, NurExone Biologic ranks worse than 242130.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NurExone Biologic's enterprise value is €28.40 Mil.
NurExone Biologic's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.36 Mil. Therefore, NurExone Biologic's EV-to-EBITDA for today is -5.30.
The historical rank and industry rank for NurExone Biologic's EV-to-EBITDA or its related term are showing as below:
FRA:J90'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.43 Med: 0 Max: 0
Current: -5.34
FRA:J90's EV-to-EBITDA is ranked worse than 100% of 413
companies
in the Biotechnology industry
Industry Median: 13.87
vs FRA:J90: -5.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NurExone Biologic's PE Ratio (TTM) for today is calculated as:
NurExone Biologic's share price for today is €0.328.
NurExone Biologic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.038.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for NurExone Biologic's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:J90 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, NurExone Biologic's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NurExone Biologic EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NurExone Biologic's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NurExone Biologic's EV-to-EBITDA falls into.
NurExone Biologic's current Enterprise Value is €28.40 Mil.
NurExone Biologic's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NurExone Biologic (FRA:J90) has a EV-to-EBITDA of -5.30 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NurExone Biologic. According to the industry distribution chart, NurExone Biologic ranks #999999 out of 413 companies in the Biotechnology industry.
Is NurExone Biologic's EV-to-EBITDA too high?
NurExone Biologic's current EV-to-EBITDA is -5.30. Based on the distribution chart, NurExone Biologic ranks #999999 out of 413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NurExone Biologic has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NurExone Biologic ranks #999999 out of 413 companies for EV-to-EBITDA. This places NurExone Biologic in the lower half of its industry. The industry median EV-to-EBITDA is 13.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.87, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NurExone Biologic. For the Biotechnology industry, the median EV-to-EBITDA is 13.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NurExone Biologic's current EV-to-EBITDA is -5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current EV-to-EBITDA of -5.30. The current EV-to-EBITDA is -5.30. NurExone Biologic's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current EV-to-EBITDA is -5.30 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
38GF Score
Get the complete analysis for FRA:J90
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J90 has been successfully added to your 
